Brief: Advaxis Announces Updated Positive Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial In NSCLC

Ayala Pharmaceuticals

27/02/2020 14:35

Feb 27 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS ANNOUNCES UPDATED POSITIVE CLINICAL DATA IN
ONGOING
PHASE 1/2 ADXS-503 TRIAL IN NSCLC AT I/O 360° CONFERENCE
    * ADVAXIS INC - KEYTRUDA SHOWED SUBSTANTIAL TUMOR SHRINKAGE
WITH
ADXS-503 TREATMENT IN COMBINATION WITH KEYTRUDA
    * ADVAXIS INC - PARTIAL RESPONSE OBSERVED IN ONE PATIENT AND
OTHER
PATIENT ACHIEVED STABLE DISEASE WITH A 25% REDUCTION IN A TARGET
LESION

Source text for Eikon:  ID:nGNXc9rn6y 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))